- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
US NIH starts human trials of universal flu vaccine
![US NIH starts human trials of universal flu vaccine US NIH starts human trials of universal flu vaccine](https://medicaldialogues.in/h-upload/2023/06/28/750x450_213020-gonorrhea-vaccine.webp)
FluMos-v2 has been designed by researchers at NIAID's Vaccine Research Center.
Bengaluru: The U.S. National Institutes of Health (NIH) said on Friday that it has begun an early-stage study on its experimental vaccine targeting six strains of influenza virus.
The vaccine candidate, FluMos-v2, is designed to offer protection against four strains of the influenza A virus and two strains of influenza B virus, the health agency said.
"An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus. With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal," said Hugh Auchincloss, acting director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
The study is expected to enroll 24 healthy volunteers, aged between 18 and 50, who will receive two intramuscular injections of FluMos-v2 at a gap of 16 weeks, NIH said.
FluMos-v2 has been designed by researchers at NIAID's Vaccine Research Center.
COVID vaccine maker Moderna said on Wednesday its flu vaccine had generated a stronger immune response against all four A and B strains of the influenza virus compared to traditional flu shots in a late-stage trial.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story